Compare GRDN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRDN | DNTH |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | 3400 | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | N/A | 2018 |
| Metric | GRDN | DNTH |
|---|---|---|
| Price | $33.42 | $55.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $33.33 | ★ $71.22 |
| AVG Volume (30 Days) | 157.2K | ★ 596.6K |
| Earning Date | 01-01-0001 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,235,000.00 |
| Revenue This Year | $19.50 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $117.77 | ★ N/A |
| Revenue Growth | N/A | ★ 120.63 |
| 52 Week Low | $17.78 | $13.37 |
| 52 Week High | $37.43 | $57.50 |
| Indicator | GRDN | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | 63.53 |
| Support Level | $31.82 | $33.94 |
| Resistance Level | $34.98 | $57.50 |
| Average True Range (ATR) | 1.19 | 3.06 |
| MACD | -0.09 | 0.32 |
| Stochastic Oscillator | 50.47 | 85.35 |
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.